Skip to main content
Journal cover image

Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma.

Publication ,  Journal Article
Beasley, GM; Terando, AM
Published in: Ann Surg Oncol
March 2024

Modern effective systemic therapy for melanoma includes two important classes of treatment: immune checkpoint inhibitors (ICIs), comprising inhibitors of cytotoxic T-lymphocyte antigen 4, programmed cell death receptor 1, and lymphocyte-activation gene 3; and small molecule BRAF/MEK inhibitor therapy. These treatments have revolutionized the management of patients with advanced melanoma and have dramatically improved clinical outcomes. The melanoma treatment landscape continues to evolve as outcome data from completed trials continue to mature and as newer studies begin to report data. In 2022 and 2023, longer-term follow-up data for established single-agent ICI therapy has been published improving our understanding of both efficacy and durability of treatment responses. A trial of a novel combination ICI therapy has demonstrated enhanced efficacy, and a study examining the order/sequence of ICI therapy versus BRAF/MEK inhibitor therapy for first-line treatment of metastatic melanoma showed that survival is improved when patients start with ICI therapy. As the indications for these therapies have expanded to the adjuvant and neoadjuvant space, we also saw the publication of 5-year results of adjuvant therapy in resected stage III patients, new data on the role of adjuvant therapy in resected stage IIB and IIC patients, and, finally, a practice-changing trial demonstrating improved outcomes using a neoadjuvant approach for patients with macroscopic disease amenable to surgical resection. In this article, we review these articles and highlight key elements for surgical oncologists.

Duke Scholars

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

March 2024

Volume

31

Issue

3

Start / End Page

1851 / 1856

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Proto-Oncogene Proteins B-raf
  • Oncology & Carcinogenesis
  • Mitogen-Activated Protein Kinase Kinases
  • Melanoma
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Beasley, G. M., & Terando, A. M. (2024). Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma. Ann Surg Oncol, 31(3), 1851–1856. https://doi.org/10.1245/s10434-023-14702-x
Beasley, Georgia M., and Alicia M. Terando. “Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma.Ann Surg Oncol 31, no. 3 (March 2024): 1851–56. https://doi.org/10.1245/s10434-023-14702-x.
Beasley GM, Terando AM. Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma. Ann Surg Oncol. 2024 Mar;31(3):1851–6.
Beasley, Georgia M., and Alicia M. Terando. “Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma.Ann Surg Oncol, vol. 31, no. 3, Mar. 2024, pp. 1851–56. Pubmed, doi:10.1245/s10434-023-14702-x.
Beasley GM, Terando AM. Articles from 2022 to 2023 to Inform Your Cancer Practice: Melanoma. Ann Surg Oncol. 2024 Mar;31(3):1851–1856.
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

March 2024

Volume

31

Issue

3

Start / End Page

1851 / 1856

Location

United States

Related Subject Headings

  • Skin Neoplasms
  • Proto-Oncogene Proteins B-raf
  • Oncology & Carcinogenesis
  • Mitogen-Activated Protein Kinase Kinases
  • Melanoma
  • Humans
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis